ImpediMed Limited (ASX:IPD)
Australia · Delayed Price · Currency is AUD 0.0190
-0.0020 (-9.52%)
Feb 5, 2026, 4:10 PM AEST
ImpediMed Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 12.72 | 10.32 | 11.34 | 10.5 | 8.35 |
Other Revenue | - | - | - | 0.07 | 0.06 |
| 12.72 | 10.32 | 11.34 | 10.57 | 8.41 | |
Revenue Growth (YoY) | 23.31% | -9.04% | 7.36% | 25.65% | 46.47% |
Cost of Revenue | 1.75 | 1.31 | 1.55 | 1.71 | 1.55 |
Gross Profit | 10.98 | 9.01 | 9.8 | 8.86 | 6.86 |
Selling, General & Admin | 26.48 | 26.19 | 25.29 | 23.67 | 24.55 |
Research & Development | 0.15 | 0.22 | 0.6 | 0.68 | 1.46 |
Other Operating Expenses | 2.79 | 3.41 | 4.31 | 3.2 | 2.12 |
Operating Expenses | 33.98 | 32.08 | 32.66 | 30.32 | 29.82 |
Operating Income | -23.01 | -23.07 | -22.87 | -21.47 | -22.97 |
Interest Expense | -1.16 | -0.09 | -0.03 | -0.03 | -0.05 |
Interest & Investment Income | 0.96 | 1.56 | 0.8 | 0.05 | 0.02 |
Other Non Operating Income (Expenses) | - | - | 1.61 | 1.62 | 1.79 |
EBT Excluding Unusual Items | -23.21 | -21.6 | -20.49 | -19.83 | -21.21 |
Asset Writedown | - | - | - | - | -0.05 |
Other Unusual Items | - | 1.85 | - | - | 0.59 |
Pretax Income | -23.21 | -19.76 | -20.49 | -19.83 | -20.67 |
Income Tax Expense | 0.03 | 0.03 | 0.03 | 0.05 | 0.04 |
Earnings From Continuing Operations | -23.24 | -19.79 | -20.52 | -19.87 | -20.71 |
Net Income | -23.24 | -19.79 | -20.52 | -19.87 | -20.71 |
Net Income to Common | -23.24 | -19.79 | -20.52 | -19.87 | -20.71 |
Shares Outstanding (Basic) | 2,019 | 2,022 | 1,800 | 1,679 | 1,202 |
Shares Outstanding (Diluted) | 2,019 | 2,022 | 1,800 | 1,679 | 1,202 |
Shares Change (YoY) | -0.13% | 12.30% | 7.23% | 39.64% | 102.01% |
EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
Free Cash Flow | -14.71 | -17.87 | -18.44 | -15.72 | -13.32 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
Gross Margin | 86.25% | 87.27% | 86.37% | 83.83% | 81.54% |
Operating Margin | -180.82% | -223.57% | -201.56% | -203.16% | -273.12% |
Profit Margin | -182.62% | -191.78% | -180.90% | -188.09% | -246.24% |
Free Cash Flow Margin | -115.57% | -173.18% | -162.56% | -148.82% | -158.45% |
EBITDA | -22.78 | -22.8 | -22.61 | -20.23 | -22.61 |
EBITDA Margin | -178.99% | -220.97% | -199.32% | -191.46% | -268.91% |
D&A For EBITDA | 0.23 | 0.27 | 0.25 | 1.24 | 0.35 |
EBIT | -23.01 | -23.07 | -22.87 | -21.47 | -22.97 |
EBIT Margin | -180.82% | -223.57% | -201.56% | -203.16% | -273.12% |
Revenue as Reported | - | - | - | 10.56 | 8.41 |
Advertising Expenses | 0.8 | 0.52 | 0.46 | 0.67 | 0.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.